Table 2.
Potential therapeutic agents for organ I/R injury targeting ferroptosis.
| I/R Injury Model | Reagents | Target | References |
|---|---|---|---|
| Myocardial I/R injury | Ferrostatin-1 | Inhibit lipid peroxidation | [73] |
| Deferoxamine | Chelation of iron | [59,163] | |
| Dexrazoxane | Chelation of iron | [164] | |
| Liproxstatin-1 | Reduce ROS levels/VDAC1 | [74] | |
| Histochrome | Increase expression of NRF2 | [75] | |
| Dexmedetomidine | AMPK/GSK-3β/Nrf2 | [76] | |
| Britanin | AMPK/GSK3β/Nrf2 | [77] | |
| Gossypol acetic acid | Inhibit lipid peroxidation | [78] | |
| Etomidate | Nrf2/HO-1 | [79] | |
| Naringenin | Nrf2/System xc-/Gpx4 | [80] | |
| Xanthohumol | Inhibit lipid peroxidation /Chelation of iron |
[81] | |
| Ferulic acid | Increase activity of antioxidant enzymes/AMPKα2 | [82] | |
| Compound 968 | Inhibit glutamine catabolism | [83] | |
| Resveratrol | Reduce oxidative stress/ USP19-Beclin1 |
[84] | |
| Cyanidin-3-Glucoside | Inhibit oxidative stress | [85] | |
| Propofol | microRNA-451/HMGB1 | [86] | |
| SR9009 | Inhibit ferritinophagy | [87] | |
| Renal I/R injury | Liproxstatin-1 | Inhibit lipid peroxidation | [92] |
| Deferoxamine | Chelation of iron | [93] | |
| Ferrostatin-1 | Inhibit lipid peroxidation | [103] | |
| 16-86 | Inhibit lipid peroxidation | [103] | |
| XJB-5-131 | GPX4, ACSL4 | [105] | |
| Dexmedetomidine | Inhibit ACSL4 via α2-AR | [106] | |
| Quercetin | ATF3 | [107] | |
| Pachymic acid | NRF2/SLC7A11/GPX4 | [108] | |
| Melatonin | NRF2/Slc7a11 | [109] | |
| Entacapone | p62/KEAP1/NRF2/Slc7a11 | [110] | |
| Cerebral I/R injury | Baicalein | GPX4/ACSL4/ACSL3 | [120] |
| Rehmannioside A | PI3K/AKT/Nrf2 and SLC7A11/GPX4 | [121] | |
| β-Caryophyllene | NRF2/HO-1 | [122] | |
| Kaempferol | Nrf2/SLC7A11/GPX4 | [123] | |
| Ferrostatin-1 | Inhibit lipid peroxidation | [115] | |
| Galangin | SLC7A11/GPX4 | [124] | |
| Carvacrol | GPX4 | [125] | |
| Carthamin yellow | Fe2+/ROS/lipid peroxidation | [126] | |
| Resveratrol | Fe2+/ROS | [127] | |
| Liproxstatin-1 | Inhibit lipid peroxidation | [115] | |
| Hepatic I/R injury | Ferrostatin-1 | Inhibit lipid peroxidation | [92,147] |
| Deferoxamine | Reduce intracellular iron | [147] | |
| Liproxstatin-1 | Inhibit lipid peroxidation | [115] | |
| α-tocopherol | Inhibit lipid peroxidation | [147] | |
| Intestinal I/R injury | APG | HO-1 and MAO-B inhibition | [142] |
| Dioscin | miR-351-5p/oxidative stress | [139] | |
| Liproxstatin-1 | Inhibit lipid peroxidation | [144] | |
| Rosiglitazone | Inhibit ACSL4 | [144] | |
| Capsiate | GPX4, TRPV1 | [143] | |
| Lung I/R injury | Liproxstatin-1 | Inhibit lipid peroxidation | [155] |
| Lidocaine | p38 MAPK pathway | [159] | |
| Rosiglitazone ACSL4 |
ACSL4 | [155] | |
| Irisin | Nrf2/HO-1 | [158] | |
| Pirfenidone | Reduce iron levels | [162] | |
| Ferrostatin-1 | Inhibit lipid peroxidation | [158] |